| Product Code: ETC6188554 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Deep | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The broader pleurisy disease market in Australia encompasses various causes, diagnosis, and treatment modalities. Integration of advanced imaging and biomarker research is enhancing diagnosis. Increased healthcare expenditure and focus on respiratory health due to rising pollution and smoking-related illnesses influence market trends.
Australias pleurisy disease market is influenced by a growing elderly population and increasing incidence of lung infections and inflammatory conditions. Research into novel anti-inflammatory drugs and supportive therapies is advancing, enhancing treatment options. Public health initiatives targeting smoking cessation and pollution control are expected to reduce pleurisy incidence over time.
The market dealing with pleurisy disease management faces challenges similar to the general pleurisy market, compounded by difficulties in managing underlying causes such as infections or autoimmune disorders. Coordination of multidisciplinary care is essential but often lacking. There is also a need for more effective treatment protocols and better diagnostic tools. Public health initiatives to reduce incidence through infection control are ongoing but variable in effectiveness.
Investors in the pleurisy disease market can explore opportunities in comprehensive healthcare services, including diagnostic, therapeutic, and rehabilitative care. The integration of telemedicine and digital health platforms in managing pleurisy enhances market attractiveness. Additionally, public awareness campaigns and preventive care products present indirect investment avenues. The market benefits from Australia robust healthcare system and increasing emphasis on chronic respiratory disease management.
Government policies addressing pleurisy as a respiratory condition integrate clinical treatment guidelines and disease surveillance programs managed by the Australia Institute of Health and Welfare (AIHW). Public health initiatives focus on controlling underlying causes such as infections and chronic diseases, supported by funding for research and health education campaigns to reduce disease burden.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Pleurisy Disease Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Pleurisy Disease Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Pleurisy Disease Market - Industry Life Cycle |
3.4 Australia Pleurisy Disease Market - Porter's Five Forces |
3.5 Australia Pleurisy Disease Market Revenues & Volume Share, By Diagnostic Type, 2021 & 2031F |
3.6 Australia Pleurisy Disease Market Revenues & Volume Share, By Treatment Type, 2021 & 2031F |
3.7 Australia Pleurisy Disease Market Revenues & Volume Share, By Route Of Administration, 2021 & 2031F |
3.8 Australia Pleurisy Disease Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 Australia Pleurisy Disease Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Australia Pleurisy Disease Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about pleurisy disease and its symptoms |
4.2.2 Rise in research and development activities for new treatment options |
4.2.3 Growing prevalence of respiratory disorders in Australia |
4.3 Market Restraints |
4.3.1 Limited availability of effective treatments for pleurisy |
4.3.2 High treatment costs associated with managing pleurisy disease |
4.3.3 Stringent regulatory requirements for approval of new therapies |
5 Australia Pleurisy Disease Market Trends |
6 Australia Pleurisy Disease Market, By Types |
6.1 Australia Pleurisy Disease Market, By Diagnostic Type |
6.1.1 Overview and Analysis |
6.1.2 Australia Pleurisy Disease Market Revenues & Volume, By Diagnostic Type, 2021- 2031F |
6.1.3 Australia Pleurisy Disease Market Revenues & Volume, By Thoracentesis, 2021- 2031F |
6.1.4 Australia Pleurisy Disease Market Revenues & Volume, By Video-Assisted Thoracic Surgery, 2021- 2031F |
6.1.5 Australia Pleurisy Disease Market Revenues & Volume, By Imaging Devices, Blood Test, 2021- 2031F |
6.1.6 Australia Pleurisy Disease Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Australia Pleurisy Disease Market, By Treatment Type |
6.2.1 Overview and Analysis |
6.2.2 Australia Pleurisy Disease Market Revenues & Volume, By Antibiotics, 2021- 2031F |
6.2.3 Australia Pleurisy Disease Market Revenues & Volume, By Antifungals, 2021- 2031F |
6.2.4 Australia Pleurisy Disease Market Revenues & Volume, By Blood Thinners, 2021- 2031F |
6.2.5 Australia Pleurisy Disease Market Revenues & Volume, By Nonsteroidal Anti-Inflammatory Drugs, 2021- 2031F |
6.2.6 Australia Pleurisy Disease Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Australia Pleurisy Disease Market, By Route Of Administration |
6.3.1 Overview and Analysis |
6.3.2 Australia Pleurisy Disease Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 Australia Pleurisy Disease Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.4 Australia Pleurisy Disease Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Australia Pleurisy Disease Market Revenues & Volume, By Hospital, 2021- 2031F |
6.4.3 Australia Pleurisy Disease Market Revenues & Volume, By Clinics, 2021- 2031F |
6.4.4 Australia Pleurisy Disease Market Revenues & Volume, By Diagnostics Laboratories, 2021- 2031F |
6.4.5 Australia Pleurisy Disease Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Australia Pleurisy Disease Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 Australia Pleurisy Disease Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.5.3 Australia Pleurisy Disease Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.5.4 Australia Pleurisy Disease Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
6.5.5 Australia Pleurisy Disease Market Revenues & Volume, By Others, 2021- 2031F |
7 Australia Pleurisy Disease Market Import-Export Trade Statistics |
7.1 Australia Pleurisy Disease Market Export to Major Countries |
7.2 Australia Pleurisy Disease Market Imports from Major Countries |
8 Australia Pleurisy Disease Market Key Performance Indicators |
8.1 Number of clinical trials focused on pleurisy treatments |
8.2 Percentage of patients diagnosed with pleurisy seeking medical care |
8.3 Adoption rate of newly developed therapies for pleurisy |
9 Australia Pleurisy Disease Market - Opportunity Assessment |
9.1 Australia Pleurisy Disease Market Opportunity Assessment, By Diagnostic Type, 2021 & 2031F |
9.2 Australia Pleurisy Disease Market Opportunity Assessment, By Treatment Type, 2021 & 2031F |
9.3 Australia Pleurisy Disease Market Opportunity Assessment, By Route Of Administration, 2021 & 2031F |
9.4 Australia Pleurisy Disease Market Opportunity Assessment, By End User, 2021 & 2031F |
9.5 Australia Pleurisy Disease Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Australia Pleurisy Disease Market - Competitive Landscape |
10.1 Australia Pleurisy Disease Market Revenue Share, By Companies, 2024 |
10.2 Australia Pleurisy Disease Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |